US FDA blesses Pfizer CML drug Bosulif
This article was originally published in Scrip
Executive Summary
Pfizer won the US FDA's nod on 4 September to market Bosulif (bosutinib), an Abl and Src kinase inhibitor, as a treatment for adults with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy, such as Novartis' Gleevec/Glivec (imatinib).